Share |

MedTech investing forum

Further innovations in MedTech to be presented at the 32nd MTi Forum

July 6, 2022

Companies developing pioneering oesophageal drug-delivery systems, innovative bio-wearables and a venture builder for MedTech and biotech advances will exclusively present in-person as Campden Wealth returns to Lausanne, Switzerland, for the 32nd edition of the MedTech Investing Europe Forum (MTi) on July 12 and 13.

The disruptive medtech company aiming to minimise patients’ need for invasive mechanical ventilation intervention

April 4, 2022

INSPIRA is developing a cost-effective respiratory support system which will function as an artificial lung for deteriorating respiratory patients. Ahead of presenting at the 32nd edition of the MedTech investing (MTi) forum on June 6 and 7, president and co-founder Joe Hayon explains the benefits and potential future applications of the system.

INSPIRA is an innovative medical device company which is developing the ART system, a cost-effective early extracorporeal respiratory support system which will function as an artificial lung for deteriorating respiratory patients.

The ART system utilises a new approach based on hemo-protective technology aimed at rebalancing oxygen saturation levels while patients are awake and breathing, potentially minimising the patient's need for invasive mechanical ventilation intervention.

The disruptive tech firm aiming to reduce the need for cataract surgery

March 31, 2022

Medtech company Edinburgh Biosciences (EBS) is working towards a global solution for the diagnosis and treatment of cataracts. Ahead of presenting at the 32nd edition of the MedTech investing (MTi) forum, chief executive officer Dr Graham Bell, explains the benefits and potential future applications of the technology.

Medtech company Edinburgh Biosciences (EBS) is working towards a global solution for the diagnosis and treatment of cataracts. Using a new light-based non-surgical treatment, this cutting-edge treatment has already proved effective in clinical trials.

Ahead of presenting at the 32nd edition of the MedTech investing (MTi) forum on June 6 and 7, Edinburgh Biosciences’ chief executive officer Dr Graham Bell, explains the benefits and potential future applications of the technology.